a Department of Psychiatry & Behavioral Sciences , McGovern Medical School, UT Health , Houston , TX , USA.
b Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina , Universidade Federal de Minas Gerais (UFMG) , Belo Horizonte , Brazil.
Expert Rev Neurother. 2019 Jan;19(1):67-81. doi: 10.1080/14737175.2019.1550361. Epub 2018 Nov 28.
Bipolar disorder (BD) is a chronic psychiatric disorder marked by clinical and pathophysiological heterogeneity. There is a high expectation that personalized approaches can improve the management of patients with BD. For that, identification and validation of potential biomarkers are fundamental. Areas covered: This manuscript will critically review the current status of different biomarkers for BD, including peripheral, genetic, neuroimaging, and neurophysiological candidates, discussing the challenges to move the field forward. Expert commentary: There are no lab or complementary tests currently recommended for the diagnosis or management of patients with BD. Panels composed by multiple biomarkers will probably contribute to stratifying patients according to their clinical stage, therapeutic response, and prognosis.
双相情感障碍 (BD) 是一种以临床和病理生理学异质性为特征的慢性精神疾病。人们高度期望个性化方法可以改善 BD 患者的管理。为此，确定和验证潜在的生物标志物是基础。
本文将批判性地回顾 BD 的不同生物标志物的当前现状，包括外周、遗传、神经影像学和神经生理学候选物，并讨论推动该领域前进的挑战。
目前尚无用于诊断或管理 BD 患者的实验室或补充检查。由多个生物标志物组成的小组可能有助于根据患者的临床阶段、治疗反应和预后对其进行分层。
